Zeloglin® cream contains hydroxypropyl chitosan
and potassium azeloyl diglycinate, two components which act
as film forming and hydrating agents, helping the product to
form an elastic film onto the skin, after application and
drying, suitable to protect the skin from chemical or
physical insults. The two components of the film,
saccharidic and lipidic, act in a synergistic way and have a
protective activity superior to that of the two components
alone, providing a greater hydration to the skin and
protection from sudden changes in temperature.
The efficacy of the product is further improved by the
presence in the formulation of UV-filters, which provide
protection from sunlight, a well-known and very common risk
factor for rosacea.
Zeloglin® cream forms a uniform and invisible
film that does
not dirty, differently from gels and lotions does not dry,
and does not give bothersome sensation, such as oily skin or
on the contrary stiff skin, like other rigid film
Zeloglin® cream is indicated to manage and relieve the
signs and symptoms of mild to moderate rosacea such as
flushing, erythema (or redness), itching, burning and
Zeloglin® cream helps to relieve dry skin by
maintaining a moist skin environment, which is beneficial to
a healing process while protecting skin from sunlight,
external agents and sudden changes of temperature.
It is also
useful for protecting skin in other chronic inflammatory
conditions of the skin, like leg and face dilation of
capillary vessels and for protection and recovery of other
facial redness (for example after sun exposure).
- Do not use if you have any known hypersensitivity to one
or more of the ingredients
- Do not use the product if the packaging is damaged or
after expiration date indicated on the tube or the box.
- Keep out of the sight and reach of children.
Uncommon side effects are application site and local
irritation reactions, including redness, rash, pruritus,
burning sensation, swelling, pain, feeling hot, dry skin,
skin tightness or exfoliation. Those effects are mostly due
to the sensitive skin of rosacea patients and appear in the
first days of application. The effects are generally mild
and transient without need to stop treatment.
Any serious incident related to the use of Zeloglin® should
be reported to the manufacturer and to the competent health
authority in your country.